Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its ...

ResMed, the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, has launched AirSense 11 in India. The company’s next-generation Continuous Positive ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

The decline in stock value comes as analysts express mixed views on the company's quarterly performance. While ResMed achieved a 10% revenue increase compared to the same quarter last year, some ...

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 millionNote: A webcast of ...

ResMed (ASX: RMD) posted a solid December quarter, with most figures slightly exceeding market expectations, driven by strong ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic global expansion.

ResMed demonstrated strong financial and operational performance in Q2 2025, supported by double-digit growth across key segments and expanding gross margins. The AirSense 11 platform and AirTouch ...